Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04154488 · ClinicalTrials.gov registry record · Phase 1
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
A Phase 1 study, sponsored by X4 Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04154488 is a Phase 1 study that has completed, run by X4 Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT04154488, a Phase 1 study, has completed, sponsored by X4 Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a 2-part study of mavorixafor in participants diagnosed with chronic neutropenia. The main goal of Part 1 (Phase 1b) is to help researchers learn more about how the investigational medicine, mavorixafor, impacts people living with chronic neutropenia (including congenital, idiopathic, and cyclic). In Part 2 (Phase 2), the safety and tolerability of chronic dosing of mavorixafor will be evaluated in a larger participant population and the impact of 6-month chronic dosing of mavorixafor on participant neutropenia.
Interventions
- DRUG Mavorixafor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-10-16 |
| Est. Completion | 2024-08-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04154488
The ClinicalTrials.gov registry entry for NCT04154488 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is X4 Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mavorixafor is the first listed.
NCT04154488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04154488 about?
NCT04154488 is a clinical study titled "A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders". This is a 2-part study of mavorixafor in participants diagnosed with chronic neutropenia. The main goal of Part 1 (Phase 1b) is to help researchers learn more about how the investigational medicine, mavorixafor, impacts people living with chronic neutropenia (including congenital, idiopathic, and cy...
What is the current status of trial NCT04154488?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2021-10-16. Estimated completion is 2024-08-27.
What interventions are being tested in trial NCT04154488?
The interventions under investigation include: Mavorixafor (DRUG).
Who is sponsoring clinical trial NCT04154488?
This trial is sponsored by X4 Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.